Barrons·8h ago
Moderna CEO's Surprising Comment Gives Clues About Where Drugmaker Is Going NextModerna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been' just a Covid vaccine company.
Moderna's transition from pandemic-driven demand to a seasonal commercial market has resulted in a severe revenue contraction, with 2026Q2 revenue of $145M down 85% from 2024Q3's $1.9B. The company's fixed-cost manufacturing footprint and persistent R&D spendi...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue has collapsed from $1.9B in 2024Q3 to $145M in 2026Q2, with gross margin deteriorating to 35.9% and net losses of -$782M in the latest quarter.
Moderna is expected to launch over ten products by 2035, with a focus on respiratory vaccines and immuno-oncology, driving a Revenue CAGR of over +15% from 2026-2035.
Moderna specializes in mRNA therapeutics, leveraging its proprietary technology platform to develop innovative medicines, including vaccines and oncology treatments.
Moderna is making progress in its personalized cancer vaccine program, including late-stage data and collaborations with Merck, positioning it as a leader in immuno-oncology.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 31, 2026 | -$1.97+3.0% vs -$2.03 | $145M+40.9% vs $103M |
Q2 2026 May 1, 2026 | -$3.40+23.6% vs -$4.45 | $389M+64.6% vs $236M |
Q1 2026 Feb 13, 2026 | -$2.11+16.9% vs -$2.54 | $678M+6.7% vs $635M |
Q4 2025 Nov 6, 2025 | -$0.51+72.7% vs -$1.87 | $1.0B+10.3% vs $921M |
Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been' just a Covid vaccine company.
Moderna, Inc. (MRNA) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Moderna NASDAQ: MRNA executives emphasized the company's evolution beyond COVID-19 vaccines during a discussion with Bernstein, highlighting its mRNA platform, personalized cancer vaccine program intismeran, rare-disease pipeline and plans to expand therapeutics development.
Moderna (MRNA +5.87%) may finally have the catalyst investors have been waiting for beyond COVID. A successful Phase 3 melanoma study strengthens the case for personalized mRNA cancer treatment, but the stock's huge rerating now leaves one question dominant: Can this become a durable oncology franchise, or has the market moved faster than the evidence?
Benchmark MRNA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Moderna, Inc. (MRNA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $182.56 | $72.44B | -25.15 | -39.23% | -145.16% | -28.87% | — | |
| $100.87 | $25.34B | -19.50 | 0.2% | -64.02% | -9.13% | — | |
| $10.83 | $1.78B | 4.26 | 64.69% | -59.87% | — | — | |
| $4.66 | $1.05B | 6.47 | 895.54% | 37.93% | 33.02% | — | |
| $27.93 | $159.19B | 20.54 | -1.65% | 6.81% | 4.87% | — | |
| $269.19 | $648B | 24.41 | 6.05% | 21.58% | 25.75% | — |
Moderna, Inc. (MRNA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Moderna, Inc. (MRNA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 31, 2026·SEC
Jul 8, 2026·SEC
May 11, 2026·SEC
Get notified when MRNA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Moderna, Inc. (MRNA) stock FAQ — growth, dividends, profitability & financials explained
Moderna, Inc. (MRNA) reported $2.23B in revenue for fiscal year 2025. This represents a 1955% increase from $108.4M in 2016.
Moderna, Inc. (MRNA) saw revenue decline by 39.2% over the past year.
Moderna, Inc. (MRNA) reported a net loss of $3.15B for fiscal year 2025.
Moderna, Inc. (MRNA) has a return on equity (ROE) of -28.9%. Negative ROE indicates the company is unprofitable.
Moderna, Inc. (MRNA) had negative free cash flow of $1.22B in fiscal year 2025, likely due to heavy capital investments.
